Mechanism of Action of OnabotulinumtoxinA in Chronic Migraine: A Narrative Review is a research paper published in Headache The Journal of Head and Face Pain (2020). On theSindex it has a DataRank of 0. It has been cited 205 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Center for Scientific Review
Grant: R37‐NS0797681
Center for Scientific Review
Grant: RO1‐NS094198
CSR NIH HHS
Grant: RO1-NS094198
NINDS NIH HHS
Grant: R01 NS094198
CSR NIH HHS
Grant: R37-NS0797681
Allergan, plc, Dublin, Ireland
FWCI
6.56
Citation Percentile
1.0%
Influential Citations
10
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals
Additional file 1 of Increase in ACC GABA+ levels correlate with decrease in migraine frequency, intensity and disability over time
Additional file 1 of Increase in ACC GABA+ levels correlate with decrease in migraine frequency, intensity and disability over time
Additional file 1 of Real-world effectiveness, satisfaction, and optimization of ubrogepant for the acute treatment of migraine in combination with onabotulinumtoxinA: results from the COURAGE Study
Additional file 1 of Real-world effectiveness, satisfaction, and optimization of ubrogepant for the acute treatment of migraine in combination with onabotulinumtoxinA: results from the COURAGE Study
Additional file 2 of Real-world effectiveness, satisfaction, and optimization of ubrogepant for the acute treatment of migraine in combination with onabotulinumtoxinA: results from the COURAGE Study
Additional file 2 of Real-world effectiveness, satisfaction, and optimization of ubrogepant for the acute treatment of migraine in combination with onabotulinumtoxinA: results from the COURAGE Study
Additional file 3 of Real-world effectiveness, satisfaction, and optimization of ubrogepant for the acute treatment of migraine in combination with onabotulinumtoxinA: results from the COURAGE Study
Additional file 3 of Real-world effectiveness, satisfaction, and optimization of ubrogepant for the acute treatment of migraine in combination with onabotulinumtoxinA: results from the COURAGE Study
Additional file 1 of CGRP-targeted medication in chronic migraine - systematic review
Additional file 1 of CGRP-targeted medication in chronic migraine - systematic review